Technology

Translate Bio

$22.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.27 (+1.21%) Today
$0.00 (0.00%) As of 9:40 PM UTC after-hours

Why Robinhood?

You can buy or sell Translate Bio and other stocks, options, and ETFs commission-free!

About TBIO

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. The listed name for TBIO is Translate Bio, Inc. Common Stock.

CEO
Ronald C. Renaud
Employees
93
Headquarters
Lexington, Massachusetts
Founded
2011
Market Cap
1.70B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
962.47K
High Today
$22.94
Low Today
$21.43
Open Price
$22.43
Volume
956.17K
52 Week High
$28.09
52 Week Low
$6.80

Collections

TBIO Earnings

-$0.58
-$0.31
-$0.04
$0.23
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

USDU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure